Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.79 USD | -1.10% | -4.79% | -0.09% |
Financials (USD)
Sales 2022 | 42.01M | Sales 2023 | 39.55M | Capitalization | 26.7M |
---|---|---|---|---|---|
Net income 2022 | -5M | Net income 2023 | -6M | EV / Sales 2022 | 0.8 x |
Net Debt 2022 | 1.2M | Net Debt 2023 | 107K | EV / Sales 2023 | 0.68 x |
P/E ratio 2022 |
-5.88
x | P/E ratio 2023 |
-4.07
x | Employees | 91 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 54.85% |
Latest transcript on Cumberland Pharmaceuticals Inc.
1 day | -1.10% | ||
1 week | -4.79% | ||
Current month | -15.96% | ||
1 month | -15.96% | ||
3 months | -5.79% | ||
6 months | -4.79% | ||
Current year | -0.09% |
Managers | Title | Age | Since |
---|---|---|---|
A. Kazimi
CEO | Chief Executive Officer | 65 | 99-01-06 |
John Hamm
DFI | Director of Finance/CFO | 67 | 18-12-31 |
James Herman
CMP | Compliance Officer | 67 | 02-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Brown
BRD | Director/Board Member | 59 | 22-07-14 |
A. Kazimi
CEO | Chief Executive Officer | 65 | 99-01-06 |
Ken Krogulski
BRD | Director/Board Member | 66 | 17-01-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 1.79 | +4.68% | 4,501 |
24-03-26 | 1.71 | 0.00% | 11,825 |
24-03-25 | 1.71 | -5.52% | 12,847 |
24-03-22 | 1.81 | 0.00% | 21,653 |
24-03-21 | 1.81 | -3.72% | 16,554 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-0.09% | 25.38M | |
+28.67% | 46.19B | |
+18.57% | 22.88B | |
+20.11% | 14.18B | |
+0.74% | 12.63B | |
+46.16% | 12.07B | |
-1.55% | 7.85B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+7.37% | 5.14B |